Skip to main content
. 2008 Nov 5;83(2):757–769. doi: 10.1128/JVI.02036-08

TABLE 3.

Contribution of anti-CD4-BS antibodies to the cross-neutralizing activity of plasmasa

Subject (% breadth) Isolate Plasma % Neutralization of flowthrough
IC50 (μg/ml) of eluted antibodies
WT gp120 BS gp120 WT gp120 BS gp120
VC10042 (100) YU2 100 (-) 100 1.2 (-)
QH0692 90 19 100 1.9 (-)
TORNO 92 15 90 6.6 (-)
JRFL 99 10 99 1.5 (-)
VC10014 (79) YU2 92 (-) 15 6.5 8.1
QH0692 52 12 28 14.5 19.1
TORNO 70 25 45 12.3 14.6
JRFL 95 5 35 7.3 10.3
CC1161 (84) YU2 89 37 65 1.4 (-)
QH0692 73 44 62 6.1 (-)
TORNO 95 82 81 1.8 3.8
JRFL 98 88 89 3.9 1.8
VC10002 (32) YU2 40 (-) (-) (-) (-)
QH0692 85 53 60 7.2 10.8
TORNO 72 52 57 8.9 15
JRFL 90 47 55 8.6 13.4
CC1508 (95) YU2 95 91 92 (-) (-)
QH0692 98 68 75 13.6 14.2
TORNO 90 82 86 8.1 13.4
JRFL 100 100 99 (-) (-)
VC20013 (63) YU2 27 12 22 (-) (-)
QH0692 78 78 72 (-) (-)
TORNO 73 73 72 (-) (-)
JRFL 70 63 58 8.4 9.7
VC20011 (5) YU2 (-) (-) (-) (-) (-)
QH0692 (-) (-) (-) (-) (-)
TORNO (-) (-) (-) (-) (-)
JRFL (-) (-) (-) (-) (-)
a

The anti-HIV-neutralizing activities of the flowthrough from the WT gp120 and the CD4-BS mutant gp120 (BS gp120) and those of the antibodies eluted from the WT gp120 and CD4-BS mutant gp120 were determined as discussed in Materials and Methods. For the plasma and flowthroughs, the percent neutralization at a 1:50 dilution is shown. Significant neutralization (≥50%) is shown in boldface. For the eluted antibodies, the IC50s are shown. (-), neutralizing activity (50% neutralization) against the indicated virus was not recorded at a 1:50 dilution. The overall breadth of neutralization for each plasma is shown under each code identifier.